Clinical Research, Multiple Sclerosis

Launched in December 2012, the Multiple Sclerosis Outcome Assessment Consortium (MSOAC) is a dynamic partnership formed to promote consensus science. Created jointly with the National Multiple Sclerosis Society,  MSOAC will collect, standardize, and analyze data about MS with the goal of qualifying a new measure of disability as a primary or secondary endpoint for future trials of MS therapies.

The National Multiple Sclerosis Society recognized the gap in the MS treatment pipeline and decided to employ a method that has steadily gained support within the research community — consortia science. MSOAC brings stakeholders from industry, academia, MS advocacy groups, and regulatory agencies together to spur the development of drug development tools to assess the effectiveness of potential treatments for all forms of MS.